ZyVersa Therapeutics, Inc. (ZVSA) – Research Study Details Role Of Inflammasomes In TNBC Brain Metastases

0 min read

Thursday, January 18, 2024

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Publication Shows Inflammasome Activity In Triple Negative Breast Cancer. A new study has been published in a peer-reviewed journal, Acta Neuropathologica Communications, showing the role of inflammasomes in the growth of brain metastases in triple-negative breast cancer (TNBC). The study found the components that form inflammasomes were upregulated and activated, starting the pathway for metastatic TNBC tumor cells to proliferate. We see this as an important potential indication for ZyVersa IC 100, a drug that blocks inflammasomes.

ZyVersa Is Developing IC 100 As An Inflammasome Inhibitor. Inflammasomes are protein complexes that assemble from three component proteins. Upon activation by pathogens or cell damage, inflammasomes form and provide signals for inflammation. Inflammasomes also form aggregates that stimulate cytokine release and maintain the inflammation process.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 


Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.